MX2019006406A - Exopolisacaridos y usos de los mismos. - Google Patents

Exopolisacaridos y usos de los mismos.

Info

Publication number
MX2019006406A
MX2019006406A MX2019006406A MX2019006406A MX2019006406A MX 2019006406 A MX2019006406 A MX 2019006406A MX 2019006406 A MX2019006406 A MX 2019006406A MX 2019006406 A MX2019006406 A MX 2019006406A MX 2019006406 A MX2019006406 A MX 2019006406A
Authority
MX
Mexico
Prior art keywords
molecules
compositions
exopolysaccharides
present
invention refers
Prior art date
Application number
MX2019006406A
Other languages
English (en)
Inventor
Domenico Guglielmetti Simone
Rossi Ruggero
FIORE Walter
Biffi Andrea
Balzaretti Silvia
Original Assignee
Sofar Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sofar Spa filed Critical Sofar Spa
Publication of MX2019006406A publication Critical patent/MX2019006406A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/04—Polysaccharides, i.e. compounds containing more than five saccharide radicals attached to each other by glycosidic bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
    • C07H13/04—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals attached to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/225—Lactobacillus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Materials Engineering (AREA)
  • Polymers & Plastics (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere a moléculas de exopolisacáridos, medios acondicionados o composiciones que comprenden las moléculas o medios. Más aún, la presente invención se refiere al uso de las moléculas de exopolisacáridos, medios acondicionados o composiciones como prebióticos, de preferencia para reforzar el sistema inmune.
MX2019006406A 2016-12-02 2017-12-01 Exopolisacaridos y usos de los mismos. MX2019006406A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT102016000122724A IT201600122724A1 (it) 2016-12-02 2016-12-02 Exopolysaccharides and uses thereof
PCT/IB2017/057576 WO2018100549A1 (en) 2016-12-02 2017-12-01 Exopolysaccharides and uses thereof

Publications (1)

Publication Number Publication Date
MX2019006406A true MX2019006406A (es) 2019-08-14

Family

ID=58609750

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019006406A MX2019006406A (es) 2016-12-02 2017-12-01 Exopolisacaridos y usos de los mismos.

Country Status (11)

Country Link
US (1) US11591416B2 (es)
EP (1) EP3548630A1 (es)
CN (1) CN110191957B (es)
AU (2) AU2017367302B2 (es)
BR (1) BR112019010867A2 (es)
CL (1) CL2019001493A1 (es)
CO (1) CO2019007116A2 (es)
IT (1) IT201600122724A1 (es)
MA (1) MA46945A (es)
MX (1) MX2019006406A (es)
WO (1) WO2018100549A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20131467A1 (it) 2013-09-06 2015-03-07 Sofar Spa Uso di una composizione comprendente microrganismi per aumentare la produzione intestinale di acido butirrico, di acido folico o di niacina e/o per diminuire la produzione intestinale di acido succinico
MA39710A (fr) 2014-04-23 2015-10-29 Sofar Spa Composition topique destinée à être utilisée dans le traitement d'une maladie inflammatoire de l'intestin
MA45327A (fr) 2016-05-13 2019-03-20 Sofar Spa Utilisation de probiotiques pour améliorer l'absorption des protéines
MA45288A (fr) 2016-06-08 2019-04-17 Sofar Spa Nouvelle utilisation médicale de probiotiques
IT201600122724A1 (it) 2016-12-02 2018-06-02 Sofar Spa Exopolysaccharides and uses thereof
IT201600127498A1 (it) 2016-12-16 2018-06-16 Sofar Spa Probiotici per uso nella diverticolosi e malattia diverticolare
EP3979982B1 (en) * 2019-06-05 2023-04-05 Lac2Biome S.R.L. Compositions comprising a bacterial strain lactobacillus paracasei and hyaluronic acid and the use thereof for the treatment of the skin
US11751597B2 (en) 2019-11-05 2023-09-12 Alfasigma S.P.A. Compositions comprising bacterial strains for use in increasing the bioavailability of amino acids derived from proteins, and related food product methods and systems

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0517363A (ja) 1991-07-11 1993-01-26 Yakult Honsha Co Ltd 抗炎症剤及びそれを含有する化粧料
CN1066926C (zh) 1996-04-08 2001-06-13 钟春燕 将椰子水发酵制作的食用纤维及其生产方法
US6461607B1 (en) 1998-08-24 2002-10-08 Ganeden Biotech, Inc. Probiotic, lactic acid-producing bacteria and uses thereof
CZ9900769A3 (cs) 1999-03-04 2000-10-11 Petr Ing. Drsc. Hušek Použití špičky s filtrem k vytvoření sloupce sorbentu s definovaným objemem v prostoru pod filtrem
US20020090416A1 (en) 1999-03-09 2002-07-11 Philip Connolly Method of enhancing absorption and utilization of protein
IT1307850B1 (it) 1999-03-15 2001-11-19 Italmed Di Galli Giovanna E Pa Composizione farmaceutica a base di fermenti lattici e carboidratinon assorbibili contenente un sale di calcio ed un sale di alluminio
EP1145643A1 (en) 2000-04-10 2001-10-17 Phillip Connolly Improved milk protein concentrate
US20040170617A1 (en) 2000-06-05 2004-09-02 Finegold Sydney M. Method of treating diseases associated with abnormal gastrointestinal flora
RU2182008C1 (ru) 2000-10-20 2002-05-10 Самойленко Игорь Иннокентьевич Вводимая перорально, ректально или интравагинально композиция, содержащая живые бактерии
PE20030284A1 (es) 2001-07-26 2003-05-01 Alimentary Health Ltd Cepas de bifidobacterium
FI20020078A (fi) 2002-01-15 2003-07-16 Danisco Immuunijärjestelmän stimulointi polydextroosilla
US6881419B2 (en) 2002-04-09 2005-04-19 William E. Lovett Vitamin formulation for enhancing bone strength
AU2002309180A1 (en) 2002-04-24 2003-11-10 Medicarb Ab Composition and kit for the treatment of inflammatory bowel diseases
NZ537499A (en) * 2002-08-06 2007-01-26 Danisco Use of lactobacillus to produce exopolysaccharides in food and pharmaceutical compositions
AU2002951270A0 (en) 2002-09-06 2002-09-19 Vri Biomedical Ltd Probiotic Bacterium and Methods of Use
WO2005001109A2 (en) 2003-05-06 2005-01-06 Government Of The United States Of America As Represented By The Sercretary Of The Department Of Health And Human Services National Institutes Of Health Methods and compositions to detect microbes in fecal samples
US20100112088A1 (en) 2003-08-29 2010-05-06 Jay Pravda Materials and methods for treatment of disorders associated with oxidative stress
EP1730302A2 (en) 2004-02-27 2006-12-13 Stichting Laboratorium voor Infectieziekten Method for detecting a microorganism in a fecal specimen
WO2005091933A2 (en) 2004-03-04 2005-10-06 E-L Management Corporation Skin treatment method with lactobacillus extract
EP2280085A3 (en) 2004-11-01 2011-02-23 George Mason University Compositions and methods for diagnosing colon disorders
EP2241195A1 (en) 2005-04-06 2010-10-20 Nestec S.A. A method and composition for nutritionally improving glucose control and insulin action
FI20051319L (fi) 2005-12-22 2007-06-23 Cyflo Oy Menetelmä eläimen ja/tai ihmisen ravitsemuksen ja hyvinvoinnin ja eläinten tuottavuuden seuraamiseksi ja kehittämiseksi
CN1840206A (zh) 2006-01-19 2006-10-04 上海交通大学 人源菌群仔猪模型的构建及仔猪肠道中菌群分子检测方法
EP1997886B1 (en) 2006-02-21 2013-06-05 National University Corporation University of Toyama Rapid method for identifying causative microorganism of infectious disease
CN101415731B (zh) 2006-02-24 2011-11-02 丘比株式会社 新型低分子透明质酸和/或其盐以及使用其的化妆品、医药组合物和食品组合物
US20100166721A1 (en) 2006-06-09 2010-07-01 Fabiola Masri Probotic compositions and uses thereof
US20080069861A1 (en) 2006-09-19 2008-03-20 National Starch And Chemical Investment Holding Corporation Probiotic/Non-Probiotic Combinations
US20080081035A1 (en) 2006-10-03 2008-04-03 National Enzyme Company Therapeutic protease compositions
US8460726B2 (en) 2006-12-18 2013-06-11 Advanced Bionutrition Corporation Dry food product containing live probiotic
EP1972208A1 (en) 2007-03-16 2008-09-24 Kirin Holdings Kabushiki Kaisha Composition for improving intestinal microflora
WO2008119012A2 (en) 2007-03-27 2008-10-02 The Procter & Gamble Company Methods and kits for administering probiotics
CA2686314C (en) * 2007-05-04 2015-10-13 Alimentary Health Limited An exopolysaccharide
NZ580972A (en) 2007-06-04 2012-02-24 Egalet Ltd Controlled release pharmaceutical compositions for prolonged effect
EP2173196B1 (en) 2007-07-06 2011-02-16 N.V. Nutricia Use of probiotics and fibers for diarrhoea
US8193155B2 (en) 2009-02-09 2012-06-05 Elc Management, Llc Method and compositions for treating skin
US20090098088A1 (en) 2007-10-10 2009-04-16 The Procter & Gamble Company Methods And Kits For The Treatment Of Diverticular Conditions
CN101240315A (zh) 2008-02-21 2008-08-13 上海交通大学 检测药物防癌效果的非损伤性分子方法
DK2318513T3 (da) * 2008-07-11 2012-10-22 Chr Hansen As Ny probiotisk bifidobacterium longum
WO2010008272A1 (en) 2008-07-15 2010-01-21 N.V. Nutricia Treatment of gut motility disorders
JP2010161944A (ja) 2009-01-13 2010-07-29 Syngen Biotech Co Ltd 新型カゼイ菌の亜種（ｓｇ９６）及びこれを含有する菌抑制組成物及びその用途
CA2754300C (en) 2009-03-05 2020-02-25 Probiotical S.P.A. Bacteria strains having a high anti-inflammatory activity
WO2010103132A1 (es) 2009-03-10 2010-09-16 Hero España, S.A. Aislamiento, identificación y caracterización de cepas con actividad probiótica a partir de heces de lactantes alimentados exclusivamente con leche materna
EP2480255B1 (en) 2009-09-23 2017-11-22 Thomas Julius Borody Therapy for chronic enteric infections
RU2012123959A (ru) 2009-11-12 2013-12-20 Нестек С.А. Питательная композиция, способствующая балансу микробиоты и оказывающая благоприятное воздействие на состояние здоровья
US20120301451A1 (en) 2009-12-22 2012-11-29 Probi Ab Non-fermented compositions comprising a cereal based fraction and a probiotic and uses thereof
US8575130B2 (en) 2010-01-04 2013-11-05 Holy Stone Healthcare Co., Ltd. Mixture of hyaluronic acid for treating and preventing inflammatory bowel disease
ITUD20100112A1 (it) 2010-06-09 2011-12-10 Farma Derma S R L Preparazione per uso vaginale e rettale e relativo procedimento di produzione
US11235008B2 (en) 2011-03-31 2022-02-01 Ganeden Biotech, Inc. Probiotic sports nutrition compositions
US20140072621A1 (en) 2011-05-09 2014-03-13 The Cleveland Clinic Foundation Composition and method to improve intestinal health
CN103917639B (zh) * 2011-09-23 2017-09-26 英特瑞克斯顿阿克图比奥帝克斯有限公司 经修饰的革兰氏阳性细菌及其用途
GB201219873D0 (en) 2012-11-05 2012-12-19 Multigerm Uk Entpr Ltd Diverticulitis treatment
CN102919922A (zh) 2012-11-08 2013-02-13 黑龙江省轻工科学研究院 一种复合益生菌发酵蓝莓果汁粉的制备方法
RU2015137415A (ru) 2013-03-05 2017-04-10 Рейксуниверситет Гронинген Применение штамма htf-f фекальной бактерии prausnitzii htf-f (dsm 26943) для подавления воспаления
CA2917109C (en) 2013-07-02 2022-11-01 Walter H. Guenzburg A method of freeze-drying encapsulated cells, freeze-dried encapsulated cells, compositions containning freeze-dried encapsulated cells and uses of such cells and compositions
ITMI20131473A1 (it) * 2013-09-06 2015-03-07 Sofar Spa Metodo per valutare gli effetti di una composizione comprendente microrganismi sul microbiota intestinale
ITMI20131467A1 (it) 2013-09-06 2015-03-07 Sofar Spa Uso di una composizione comprendente microrganismi per aumentare la produzione intestinale di acido butirrico, di acido folico o di niacina e/o per diminuire la produzione intestinale di acido succinico
MA39710A (fr) 2014-04-23 2015-10-29 Sofar Spa Composition topique destinée à être utilisée dans le traitement d'une maladie inflammatoire de l'intestin
AU2015258769A1 (en) 2014-05-12 2016-12-01 Medlab Ip Pty Ltd Probiotic compositions and uses thereof for treatment of obesity-related disorders
PL2990045T3 (pl) 2014-08-26 2017-05-31 Chr. Hansen A/S Bifidobacterium animalis podgat. lactis do stosowania w zmniejszaniu bólu brzucha u kobiet po menopauzie
WO2017195182A1 (en) 2016-05-13 2017-11-16 Sofar S.P.A. Use of probiotics for improving protein absorption
MA45327A (fr) 2016-05-13 2019-03-20 Sofar Spa Utilisation de probiotiques pour améliorer l'absorption des protéines
MA45288A (fr) 2016-06-08 2019-04-17 Sofar Spa Nouvelle utilisation médicale de probiotiques
IT201600122724A1 (it) 2016-12-02 2018-06-02 Sofar Spa Exopolysaccharides and uses thereof
ES2965306T3 (es) 2016-12-16 2024-04-12 Gervais Danone Sa Composición probiótica que comprende cepas de Lactobacillus rhamnosus y Lactobacillus paracasei
IT201600127498A1 (it) 2016-12-16 2018-06-16 Sofar Spa Probiotici per uso nella diverticolosi e malattia diverticolare
WO2019019961A1 (zh) 2017-07-26 2019-01-31 海思科医药集团股份有限公司 防治消化道和/或皮肤反应的菌群及其应用
IT201700101704A1 (it) 2017-09-12 2019-03-12 Sofar Spa Nuovo uso per trattamento delle infezioni da clostridium difficile
WO2019111189A1 (en) 2017-12-06 2019-06-13 Sofar S.P.A. Composition based on probiotics and uses thereof
CN108743851A (zh) 2018-08-09 2018-11-06 深圳市博奥生物科技有限公司 一种复合益生菌粉的制备方法及复合益生菌粉
IT201900016805A1 (it) 2019-09-20 2021-03-20 Sofar Spa Ceppi batterici, loro composizioni e loro uso per il trattamento di disturbi gastrointestinali
IT201900016850A1 (it) 2019-09-20 2021-03-20 Sofar Spa Composizioni a base di ceppi batterici e estratti di bacche e loro uso come antinfiammatori
IT201900016811A1 (it) 2019-09-20 2021-03-20 Sofar Spa Ceppi batterici, loro composizioni e loro uso per il trattamento di disturbi gastrointestinali
IT201900016865A1 (it) 2019-09-20 2021-03-20 Sofar Spa Composizioni a base di ceppi batterici e loro uso come antinfiammatori
IT201900020422A1 (it) 2019-11-05 2021-05-05 Sofar Spa Composizioni comprendenti ceppi di batteri per uso per aumentare la biodisponibilità degli amminoacidi derivanti da proteine
US11751597B2 (en) 2019-11-05 2023-09-12 Alfasigma S.P.A. Compositions comprising bacterial strains for use in increasing the bioavailability of amino acids derived from proteins, and related food product methods and systems

Also Published As

Publication number Publication date
US20190345268A1 (en) 2019-11-14
AU2017367302A1 (en) 2019-06-20
CL2019001493A1 (es) 2019-08-30
US11591416B2 (en) 2023-02-28
CN110191957B (zh) 2023-07-28
AU2022204885A1 (en) 2022-07-28
CN110191957A (zh) 2019-08-30
AU2017367302B2 (en) 2022-07-28
MA46945A (fr) 2021-03-17
CO2019007116A2 (es) 2019-09-09
WO2018100549A1 (en) 2018-06-07
EP3548630A1 (en) 2019-10-09
IT201600122724A1 (it) 2018-06-02
BR112019010867A2 (pt) 2019-10-22

Similar Documents

Publication Publication Date Title
MX2019006406A (es) Exopolisacaridos y usos de los mismos.
PH12019502283A1 (en) Anti-lag3 antibodies
PH12018500950A1 (en) Subcutaneous formulations of anti-cd38 antibodies and their uses
MX2018000147A (es) Moleculas de anticuerpo que se unen al grupo de diferenciacion 45 (cd45).
MX2022005173A (es) Anticuerpos anti-promiostatina o miostatina latente y usos de los mismos.
MX2018008369A (es) Anticuerpos de anti-miostatina pro/latente y metodo de uso de los mismos.
MX2017004838A (es) Composiciones de interleucina-15 y usos de estas.
MX2018000470A (es) Moleculas de anticuerpo que se unen al grupo de diferenciacion 22 (cd22).
MX2018007423A (es) Moleculas de anticuerpo que se unen a pd-1 y usos de las mismas.
MY197345A (en) Antibody molecules to april and uses thereof
TR201908550T4 (tr) Profilaktik veya terapötik uygulamalar için lipozomal sferik nükleik asitler tarafından immün modülatörlerin çok değerlikli teslimi.
MX2016014807A (es) Singenes de alfa(1,2)fucosiltransferasa para su utilizacion en la produccion de oligosacaridos fucosilados.
MX2016016881A (es) Anticuerpos que se unen a axl.
MX2018000590A (es) Moleculas de anticuerpo que se unen a agrupacion de diferenciacion 79 (cd79).
MX2018007304A (es) Composiciones de interleucina-15 y sus usos.
MX2016008096A (es) Tratamiento de superficies de particulas y uso de las mismas.
AU2017317563A8 (en) Detergent compositions comprising xanthan lyase variants I
BR112017013170A2 (pt) enxerto de ciclodextrina por ligações amida a um éter ácido hialurônico reticulado e usos do mesmo
PH12018502137A1 (en) Anti-complement factor bb antibodies and uses thereof
PH12018501279A1 (en) Compositions comprising 15-hepe and methods of using the same
MX2017008390A (es) Uretanos funcionalizados con alcoxisilano y funcionalizados con alofanato.
PH12016501658A1 (en) Sialylated glycoprotein compositions and uses thereof
WO2017106683A3 (en) Concatemeric rna molecules, compositions, and methods and uses thereof
PH12017500148A1 (en) Hair products containing branched amine functionalized silicone compounds